The Cullen Capital Management LLC Acquires 32,745 Shares of Merck & Company, Inc. (MRK), Report finds

The Cullen Capital Management LLC Acquires 32,745 Shares of Merck & Company, Inc. (MRK), Report finds

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in Merck & Company by 1.9% in the second quarter. Vanguard Group Inc. now owns 174,819,694 shares of the company’s stock worth $10,071,362,000 after buying an additional 3,242,254 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in Merck & Company by 0.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 74,363,785 shares of the company’s stock worth $4,284,098,000 after buying an additional 535,407 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Merck & Company by 2.2% in the third quarter. Bank of New York Mellon Corp now owns 56,714,385 shares of the company’s stock worth $3,539,544,000 after buying an additional 1,235,395 shares during the last quarter. BlackRock Fund Advisors boosted its position in Merck & Company by 4.0% in the second quarter. BlackRock Fund Advisors now owns 44,732,600 shares of the company’s stock worth $2,577,045,000 after buying an additional 1,701,520 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Merck & Company by 1.1% in the third quarter. Northern Trust Corp now owns 36,237,082 shares of the company’s stock worth $2,261,555,000 after buying an additional 411,890 shares during the last quarter. 74.10% of the stock is currently owned by hedge funds and other institutional investors.

Cullen Capital Management LLC boosted its stake in shares of Merck & Company, Inc. (NYSE:MRK) by 2.3% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,487,815 shares of the company’s stock after buying an additional 32,745 shares during the period. Merck & Company comprises about 3.1% of Cullen Capital Management LLC’s holdings, making the stock its 6th largest position. Cullen Capital Management LLC’s holdings in Merck & Company were worth $92,855,000 at the end of the most recent quarter.

Shares of Merck & Company, Inc. (NYSE:MRK) opened at 64.15 on Monday. The stock has a 50 day moving average price of $61.60 and a 200 day moving average price of $61.72. Merck & Company, Inc. has a 12-month low of $49.24 and a 12-month high of $65.46. The firm has a market capitalization of $176.87 billion, a P/E ratio of 31.45 and a beta of 0.79.

Merck & Company (NYSE:MRK) last released its quarterly earnings results on Thursday, February 2nd. The company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.89 by $0.00. The firm had revenue of $10.10 billion for the quarter, compared to analyst estimates of $10.22 billion. Merck & Company had a return on equity of 24.08% and a net margin of 14.30%. Merck & Company’s revenue for the quarter was down 1.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.93 EPS. Equities analysts anticipate that Merck & Company, Inc. will post $3.81 earnings per share for the current fiscal year.

MRK has been the topic of a number of recent analyst reports. Vetr cut shares of Merck & Company from a “sell” rating to a “strong sell” rating and set a $52.27 target price on the stock. in a research report on Tuesday, December 27th. Bryan, Garnier & Co assumed coverage on shares of Merck & Company in a research note on Friday, January 13th. They set a “buy” rating on the stock. Zacks Investment Research upgraded shares of Merck & Company from a “hold” rating to a “buy” rating and set a $69.00 price target on the stock in a research note on Wednesday, November 23rd. Jefferies Group LLC lowered shares of Merck & Company from a “hold” rating to an “underperform” rating and set a $48.00 price target on the stock. in a research note on Monday, December 19th. Finally, J P Morgan Chase & Co reiterated a “buy” rating on shares of Merck & Company in a research note on Wednesday, January 11th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company. Merck & Company has a consensus rating of “Buy” and an average price target of $66.91.

In related news, Director Patricia F. Russo sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 8th. The stock was sold at an average price of $64.42, for a total transaction of $322,100.00. Following the transaction, the director now directly owns 18,148 shares of the company’s stock, valued at approximately $1,169,094.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael J. Holston sold 91,959 shares of the business’s stock in a transaction that occurred on Friday, February 3rd. The stock was sold at an average price of $63.96, for a total value of $5,881,697.64. Following the transaction, the executive vice president now directly owns 105,559 shares in the company, valued at $6,751,553.64. The disclosure for this sale can be found here. Insiders have sold a total of 106,959 shares of company stock worth $6,843,448 over the last three months. 0.05% of the stock is currently owned by corporate insiders.

About Merck & Company

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Related posts

Leave a Comment